Israel Englander Nuvalent, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 81,914 shares of NUVL stock, worth $6.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

81,914

Previous 181,206 54.8%

Holding current value

$6.02 Million

Previous $14.2 Million 59.05%

% of portfolio

0.0%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$67.38 - $88.96 $6.69 Million - $8.83 Million	-99,292 Reduced 54.8%	81,914 $5.81 Million
Q4 2024 Feb 14, 2025	BUY	$77.87 - $104.93 $66,500 - $89,610	854 Added 0.47%	181,206 $14.2 Million
Q3 2024 Nov 14, 2024	BUY	$67.44 - $112.17 $10.3 Million - $17.1 Million	152,465 Added 546.72%	180,352 $18.5 Million
Q2 2024 Aug 14, 2024	SELL	$62.76 - $81.61 $178,614 - $232,262	-2,846 Reduced 9.26%	27,887 $2.12 Million
Q1 2024 May 15, 2024	SELL	$72.35 - $88.99 $682,332 - $839,264	-9,431 Reduced 23.48%	30,733 $2.31 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $1.7 Million - $3.22 Million	40,164 New	40,164 $2.96 Million
Q1 2023 May 15, 2023	SELL	$25.42 - $33.52 $4.06 Million - $5.35 Million	-159,523 Reduced 73.46%	57,633 $1.5 Million
Q4 2022 Feb 14, 2023	BUY	$18.46 - $36.37 $1.13 Million - $2.22 Million	60,993 Added 39.06%	217,156 $6.47 Million
Q3 2022 Nov 14, 2022	SELL	$13.55 - $19.92 $1.4 Million - $2.06 Million	-103,626 Reduced 39.89%	156,163 $3.04 Million

Others Institutions Holding NUVL

# of Institutions

216

Shares Held

60.9M

Call Options Held

319K

Put Options Held

211K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.16B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account